http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 15 May 2026 06:25:33 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/BTIG+Reiterates+Neutral+Rating+on+Insight+Molecular+Diagnostics+Inc.+%28IMDX%29/26498542.html <p>BTIG analyst Mark Massaro reiterated a Neutral rating on Insight Molecular Diagnostics Inc. (NASDAQ: IMDX).</p><p>The analyst commented: "Insight Molecular Diagnostics is the first company (that we are aware of) to submit to the FDA for a kitted test (in late March 2026) for kidney transplant testing. IMDX is on the clock with the FDA and the company believes it is on track to obtain an FDA approval for its GraftAssureDx kitted transplant test by the end of 2026. We think a decentralized and regulated (FDA-cleared and CE-marked) transplant kitted product should resonate well, particularly OUS, enable labs to run their http://www.streetinsider.com/Analyst+Comments/BTIG+Reiterates+Neutral+Rating+on+Insight+Molecular+Diagnostics+Inc.+%28IMDX%29/26498542.html Fri, 15 May 2026 06:25:33 -0400 IMDX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Insight+Molecular+Diagno++For%3A+Mar+31/26486243.html si-local-file:///var/storage/secattach/20260513/26486243.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Insight+Molecular+Diagno++For%3A+Mar+31/26486243.html Wed, 13 May 2026 16:16:00 -0400 IMDX O.07511324 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Insight+Molecular+Diagno++For%3A+Mar+31/26486243.html si-local-file:///var/storage/secattach/20260513/26486243.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Insight+Molecular+Diagno++For%3A+Mar+31/26486243.html Wed, 13 May 2026 16:16:00 -0400 IMDX O.07511324 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Insight+Molecular+Diagno++For%3A+May+13/26486069.html si-local-file:///var/storage/secattach/20260513/26486069.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Insight+Molecular+Diagno++For%3A+May+13/26486069.html Wed, 13 May 2026 16:10:00 -0400 IMDX O.07511324 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Insight+Molecular+Diagno++For%3A+May+13/26486069.html si-local-file:///var/storage/secattach/20260513/26486069.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Insight+Molecular+Diagno++For%3A+May+13/26486069.html Wed, 13 May 2026 16:10:00 -0400 IMDX O.07511324 http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Insight+Molecular+Diagno++For%3A+Feb+20/26485895.html si-local-file:///var/storage/secattach/20260513/26485895.html http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Insight+Molecular+Diagno++For%3A+Feb+20/26485895.html Wed, 13 May 2026 16:06:00 -0400 IMDX O.07511324 http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Insight+Molecular+Diagno++For%3A+Feb+20/26485895.html si-local-file:///var/storage/secattach/20260513/26485895.html http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Insight+Molecular+Diagno++For%3A+Feb+20/26485895.html Wed, 13 May 2026 16:06:00 -0400 IMDX O.07511324 http://www.streetinsider.com/Press+Releases/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html <ul type="disc"><li style="margin-bottom:8pt;">Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement</li><li style="margin-bottom:8pt;">Northeast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial agreement to participate in GALACTIC study</li><li style="margin-bottom:8pt;">Booked research-use-only purchase by E.U. transplant center and APAC purchase expected in coming days</li><li style="margin-bottom:8pt;">Anticipate significant U.S. orders to follow FDA marketing authorization</li><li style="margin-bottom:8pt;">Encouraging dialogue with FDA supports expected authorization later in 2026 <br/><br/></li></ul> <p>NASHVILLE, Tenn., May 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with http://www.streetinsider.com/Press+Releases/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html Wed, 13 May 2026 16:05:00 -0400 A.03186153 A.06822034 A.50215103 A.50216777 IMDX O.07511324 O.20026344 O.28798549 O.50921235 O.54516537 http://www.streetinsider.com/Press+Releases/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html <ul type="disc"><li style="margin-bottom:8pt;">Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement</li><li style="margin-bottom:8pt;">Northeast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial agreement to participate in GALACTIC study</li><li style="margin-bottom:8pt;">Booked research-use-only purchase by E.U. transplant center and APAC purchase expected in coming days</li><li style="margin-bottom:8pt;">Anticipate significant U.S. orders to follow FDA marketing authorization</li><li style="margin-bottom:8pt;">Encouraging dialogue with FDA supports expected authorization later in 2026 <br/><br/></li></ul> <p>NASHVILLE, Tenn., May 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with http://www.streetinsider.com/Press+Releases/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html Wed, 13 May 2026 16:05:00 -0400 A.03186153 A.06822034 A.50215103 A.50216777 IMDX O.07511324 O.20026344 O.28798549 O.50921235 O.54516537 http://www.streetinsider.com/Press+Releases/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html <ul type="disc"><li style="margin-bottom:8pt;">Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement</li><li style="margin-bottom:8pt;">Northeast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial agreement to participate in GALACTIC study</li><li style="margin-bottom:8pt;">Booked research-use-only purchase by E.U. transplant center and APAC purchase expected in coming days</li><li style="margin-bottom:8pt;">Anticipate significant U.S. orders to follow FDA marketing authorization</li><li style="margin-bottom:8pt;">Encouraging dialogue with FDA supports expected authorization later in 2026 <br/><br/></li></ul> <p>NASHVILLE, Tenn., May 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with http://www.streetinsider.com/Press+Releases/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html Wed, 13 May 2026 16:05:00 -0400 A.03186153 A.06822034 A.50215103 A.50216777 IMDX O.07511324 O.20026344 O.28798549 O.50921235 O.54516537 http://www.streetinsider.com/Press+Releases/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html <ul type="disc"><li style="margin-bottom:8pt;">Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement</li><li style="margin-bottom:8pt;">Northeast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial agreement to participate in GALACTIC study</li><li style="margin-bottom:8pt;">Booked research-use-only purchase by E.U. transplant center and APAC purchase expected in coming days</li><li style="margin-bottom:8pt;">Anticipate significant U.S. orders to follow FDA marketing authorization</li><li style="margin-bottom:8pt;">Encouraging dialogue with FDA supports expected authorization later in 2026 <br/><br/></li></ul> <p>NASHVILLE, Tenn., May 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with http://www.streetinsider.com/Press+Releases/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html Wed, 13 May 2026 16:05:00 -0400 A.03186153 A.06822034 A.50215103 A.50216777 IMDX O.07511324 O.20026344 O.28798549 O.50921235 O.54516537 http://www.streetinsider.com/Press+Releases/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html <ul type="disc"><li style="margin-bottom:8pt;">Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement</li><li style="margin-bottom:8pt;">Northeast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial agreement to participate in GALACTIC study</li><li style="margin-bottom:8pt;">Booked research-use-only purchase by E.U. transplant center and APAC purchase expected in coming days</li><li style="margin-bottom:8pt;">Anticipate significant U.S. orders to follow FDA marketing authorization</li><li style="margin-bottom:8pt;">Encouraging dialogue with FDA supports expected authorization later in 2026 <br/><br/></li></ul> <p>NASHVILLE, Tenn., May 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with http://www.streetinsider.com/Press+Releases/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html Wed, 13 May 2026 16:05:00 -0400 A.03186153 A.06822034 A.50215103 A.50216777 IMDX O.07511324 O.20026344 O.28798549 O.50921235 O.54516537 http://www.streetinsider.com/Press+Releases/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html <ul type="disc"><li style="margin-bottom:8pt;">Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement</li><li style="margin-bottom:8pt;">Northeast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial agreement to participate in GALACTIC study</li><li style="margin-bottom:8pt;">Booked research-use-only purchase by E.U. transplant center and APAC purchase expected in coming days</li><li style="margin-bottom:8pt;">Anticipate significant U.S. orders to follow FDA marketing authorization</li><li style="margin-bottom:8pt;">Encouraging dialogue with FDA supports expected authorization later in 2026 <br/><br/></li></ul> <p>NASHVILLE, Tenn., May 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with http://www.streetinsider.com/Press+Releases/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html Wed, 13 May 2026 16:05:00 -0400 A.03186153 A.06822034 A.50215103 A.50216777 IMDX O.07511324 O.20026344 O.28798549 O.50921235 O.54516537 http://www.streetinsider.com/Press+Releases/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html <ul type="disc"><li style="margin-bottom:8pt;">Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement</li><li style="margin-bottom:8pt;">Northeast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial agreement to participate in GALACTIC study</li><li style="margin-bottom:8pt;">Booked research-use-only purchase by E.U. transplant center and APAC purchase expected in coming days</li><li style="margin-bottom:8pt;">Anticipate significant U.S. orders to follow FDA marketing authorization</li><li style="margin-bottom:8pt;">Encouraging dialogue with FDA supports expected authorization later in 2026 <br/><br/></li></ul> <p>NASHVILLE, Tenn., May 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with http://www.streetinsider.com/Press+Releases/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html Wed, 13 May 2026 16:05:00 -0400 A.03186153 A.06822034 A.50215103 A.50216777 IMDX O.07511324 O.20026344 O.28798549 O.50921235 O.54516537 http://www.streetinsider.com/Press+Releases/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html <ul type="disc"><li style="margin-bottom:8pt;">Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement</li><li style="margin-bottom:8pt;">Northeast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial agreement to participate in GALACTIC study</li><li style="margin-bottom:8pt;">Booked research-use-only purchase by E.U. transplant center and APAC purchase expected in coming days</li><li style="margin-bottom:8pt;">Anticipate significant U.S. orders to follow FDA marketing authorization</li><li style="margin-bottom:8pt;">Encouraging dialogue with FDA supports expected authorization later in 2026 <br/><br/></li></ul> <p>NASHVILLE, Tenn., May 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with http://www.streetinsider.com/Press+Releases/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html Wed, 13 May 2026 16:05:00 -0400 A.03186153 A.06822034 A.50215103 A.50216777 IMDX O.07511324 O.20026344 O.28798549 O.50921235 O.54516537 http://www.streetinsider.com/Press+Releases/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html <ul type="disc"><li style="margin-bottom:8pt;">Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement</li><li style="margin-bottom:8pt;">Northeast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial agreement to participate in GALACTIC study</li><li style="margin-bottom:8pt;">Booked research-use-only purchase by E.U. transplant center and APAC purchase expected in coming days</li><li style="margin-bottom:8pt;">Anticipate significant U.S. orders to follow FDA marketing authorization</li><li style="margin-bottom:8pt;">Encouraging dialogue with FDA supports expected authorization later in 2026 <br/><br/></li></ul> <p>NASHVILLE, Tenn., May 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with http://www.streetinsider.com/Press+Releases/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html Wed, 13 May 2026 16:05:00 -0400 A.03186153 A.06822034 A.50215103 A.50216777 IMDX O.07511324 O.20026344 O.28798549 O.50921235 O.54516537 http://www.streetinsider.com/Press+Releases/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html <ul type="disc"><li style="margin-bottom:8pt;">Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement</li><li style="margin-bottom:8pt;">Northeast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial agreement to participate in GALACTIC study</li><li style="margin-bottom:8pt;">Booked research-use-only purchase by E.U. transplant center and APAC purchase expected in coming days</li><li style="margin-bottom:8pt;">Anticipate significant U.S. orders to follow FDA marketing authorization</li><li style="margin-bottom:8pt;">Encouraging dialogue with FDA supports expected authorization later in 2026 <br/><br/></li></ul> <p>NASHVILLE, Tenn., May 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with http://www.streetinsider.com/Press+Releases/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html Wed, 13 May 2026 16:05:00 -0400 A.03186153 A.06822034 A.50215103 A.50216777 IMDX O.07511324 O.20026344 O.28798549 O.50921235 O.54516537 http://www.streetinsider.com/Globe+Newswire/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html <ul type="disc"><li style="margin-bottom:8pt;">Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement</li><li style="margin-bottom:8pt;">Northeast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial agreement to participate in GALACTIC study</li><li style="margin-bottom:8pt;">Booked research-use-only purchase by E.U. transplant center and APAC purchase expected in coming days</li><li style="margin-bottom:8pt;">Anticipate significant U.S. orders to follow FDA marketing authorization</li><li style="margin-bottom:8pt;">Encouraging dialogue with FDA supports expected authorization later in 2026 <br/><br/></li></ul> <p>NASHVILLE, Tenn., May 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with http://www.streetinsider.com/Globe+Newswire/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html Wed, 13 May 2026 16:05:00 -0400 A.03186153 A.06822034 A.50215103 A.50216777 IMDX O.07511324 O.20026344 O.28798549 O.50921235 O.54516537 http://www.streetinsider.com/Globe+Newswire/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html <ul type="disc"><li style="margin-bottom:8pt;">Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement</li><li style="margin-bottom:8pt;">Northeast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial agreement to participate in GALACTIC study</li><li style="margin-bottom:8pt;">Booked research-use-only purchase by E.U. transplant center and APAC purchase expected in coming days</li><li style="margin-bottom:8pt;">Anticipate significant U.S. orders to follow FDA marketing authorization</li><li style="margin-bottom:8pt;">Encouraging dialogue with FDA supports expected authorization later in 2026 <br/><br/></li></ul> <p>NASHVILLE, Tenn., May 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with http://www.streetinsider.com/Globe+Newswire/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html Wed, 13 May 2026 16:05:00 -0400 A.03186153 A.06822034 A.50215103 A.50216777 IMDX O.07511324 O.20026344 O.28798549 O.50921235 O.54516537 http://www.streetinsider.com/Globe+Newswire/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html <ul type="disc"><li style="margin-bottom:8pt;">Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement</li><li style="margin-bottom:8pt;">Northeast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial agreement to participate in GALACTIC study</li><li style="margin-bottom:8pt;">Booked research-use-only purchase by E.U. transplant center and APAC purchase expected in coming days</li><li style="margin-bottom:8pt;">Anticipate significant U.S. orders to follow FDA marketing authorization</li><li style="margin-bottom:8pt;">Encouraging dialogue with FDA supports expected authorization later in 2026 <br/><br/></li></ul> <p>NASHVILLE, Tenn., May 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with http://www.streetinsider.com/Globe+Newswire/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html Wed, 13 May 2026 16:05:00 -0400 A.03186153 A.06822034 A.50215103 A.50216777 IMDX O.07511324 O.20026344 O.28798549 O.50921235 O.54516537 http://www.streetinsider.com/Globe+Newswire/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html <ul type="disc"><li style="margin-bottom:8pt;">Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement</li><li style="margin-bottom:8pt;">Northeast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial agreement to participate in GALACTIC study</li><li style="margin-bottom:8pt;">Booked research-use-only purchase by E.U. transplant center and APAC purchase expected in coming days</li><li style="margin-bottom:8pt;">Anticipate significant U.S. orders to follow FDA marketing authorization</li><li style="margin-bottom:8pt;">Encouraging dialogue with FDA supports expected authorization later in 2026 <br/><br/></li></ul> <p>NASHVILLE, Tenn., May 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with http://www.streetinsider.com/Globe+Newswire/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html Wed, 13 May 2026 16:05:00 -0400 A.03186153 A.06822034 A.50215103 A.50216777 IMDX O.07511324 O.20026344 O.28798549 O.50921235 O.54516537 http://www.streetinsider.com/Globe+Newswire/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html <ul type="disc"><li style="margin-bottom:8pt;">Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement</li><li style="margin-bottom:8pt;">Northeast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial agreement to participate in GALACTIC study</li><li style="margin-bottom:8pt;">Booked research-use-only purchase by E.U. transplant center and APAC purchase expected in coming days</li><li style="margin-bottom:8pt;">Anticipate significant U.S. orders to follow FDA marketing authorization</li><li style="margin-bottom:8pt;">Encouraging dialogue with FDA supports expected authorization later in 2026 <br/><br/></li></ul> <p>NASHVILLE, Tenn., May 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with http://www.streetinsider.com/Globe+Newswire/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html Wed, 13 May 2026 16:05:00 -0400 A.03186153 A.06822034 A.50215103 A.50216777 IMDX O.07511324 O.20026344 O.28798549 O.50921235 O.54516537 http://www.streetinsider.com/Globe+Newswire/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html <ul type="disc"><li style="margin-bottom:8pt;">Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement</li><li style="margin-bottom:8pt;">Northeast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial agreement to participate in GALACTIC study</li><li style="margin-bottom:8pt;">Booked research-use-only purchase by E.U. transplant center and APAC purchase expected in coming days</li><li style="margin-bottom:8pt;">Anticipate significant U.S. orders to follow FDA marketing authorization</li><li style="margin-bottom:8pt;">Encouraging dialogue with FDA supports expected authorization later in 2026 <br/><br/></li></ul> <p>NASHVILLE, Tenn., May 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with http://www.streetinsider.com/Globe+Newswire/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html Wed, 13 May 2026 16:05:00 -0400 A.03186153 A.06822034 A.50215103 A.50216777 IMDX O.07511324 O.20026344 O.28798549 O.50921235 O.54516537 http://www.streetinsider.com/Globe+Newswire/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html <ul type="disc"><li style="margin-bottom:8pt;">Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement</li><li style="margin-bottom:8pt;">Northeast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial agreement to participate in GALACTIC study</li><li style="margin-bottom:8pt;">Booked research-use-only purchase by E.U. transplant center and APAC purchase expected in coming days</li><li style="margin-bottom:8pt;">Anticipate significant U.S. orders to follow FDA marketing authorization</li><li style="margin-bottom:8pt;">Encouraging dialogue with FDA supports expected authorization later in 2026 <br/><br/></li></ul> <p>NASHVILLE, Tenn., May 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with http://www.streetinsider.com/Globe+Newswire/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html Wed, 13 May 2026 16:05:00 -0400 A.03186153 A.06822034 A.50215103 A.50216777 IMDX O.07511324 O.20026344 O.28798549 O.50921235 O.54516537 http://www.streetinsider.com/Globe+Newswire/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html <ul type="disc"><li style="margin-bottom:8pt;">Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement</li><li style="margin-bottom:8pt;">Northeast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial agreement to participate in GALACTIC study</li><li style="margin-bottom:8pt;">Booked research-use-only purchase by E.U. transplant center and APAC purchase expected in coming days</li><li style="margin-bottom:8pt;">Anticipate significant U.S. orders to follow FDA marketing authorization</li><li style="margin-bottom:8pt;">Encouraging dialogue with FDA supports expected authorization later in 2026 <br/><br/></li></ul> <p>NASHVILLE, Tenn., May 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with http://www.streetinsider.com/Globe+Newswire/IMDX+Reports+Q1+2026+Results+and+Update+on+Progress+Toward+GraftAssure+Commercialization/26485835.html Wed, 13 May 2026 16:05:00 -0400 A.03186153 A.06822034 A.50215103 A.50216777 IMDX O.07511324 O.20026344 O.28798549 O.50921235 O.54516537